JANX logo

JANX
Janux Therapeutics Inc

1,647
Mkt Cap
$902.74M
Volume
1.31M
52W High
$35.34
52W Low
$12.12
PE Ratio
-8.09
JANX Fundamentals
Price
$14.84
Prev Close
$14.51
Open
$14.22
50D MA
$13.74
Beta
1.45
Avg. Volume
1.16M
EPS (Annual)
-$1.83
P/B
0.94
Rev/Employee
$91,743.12
$89.28
Loading...
Loading...
News
all
press releases
Janux Therapeutics Secures $35M Milestone Payment From BMY Deal
JANX earns $35M milestone payment from Bristol Myers as TRACTr-based cancer candidate advances, signaling progress in its tumor-activated therapy platform.
Zacks·22h ago
News Placeholder
More News
News Placeholder
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the nomination of a development...
Business Wire·2d ago
News Placeholder
Janux Therapeutics (NASDAQ:JANX) Downgraded by Wall Street Zen to "Sell"
Wall Street Zen downgraded Janux Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat·6d ago
News Placeholder
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the fourteen ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have is...
MarketBeat·11d ago
News Placeholder
Cantor Fitzgerald Has Lowered Expectations for Janux Therapeutics (NASDAQ:JANX) Stock Price
Cantor Fitzgerald reduced their price target on shares of Janux Therapeutics from $150.00 to $100.00 and set an "overweight" rating on the stock in a research report on Friday...
MarketBeat·1mo ago
News Placeholder
Janux Therapeutics, Inc. Q4 Loss Rises
(RTTNews) - Janux Therapeutics, Inc. (JANX) released Loss for its fourth quarter of -$42.40 million...
Nasdaq News: Markets·1mo ago
News Placeholder
Janux Therapeutics (NASDAQ:JANX) Releases Quarterly Earnings Results, Beats Expectations By $0.14 EPS
Janux Therapeutics (NASDAQ:JANX - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of...
MarketBeat·1mo ago
News Placeholder
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the fourth...
Business Wire·1mo ago
News Placeholder
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Rating of "Moderate Buy" from Analysts
Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the fifteen research firms that are presently covering the stock, Marketbeat.com...
MarketBeat·1mo ago
News Placeholder
Readystate Asset Management LP Boosts Stock Holdings in Janux Therapeutics, Inc. $JANX
Readystate Asset Management LP lifted its position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 38.0% in the 3rd quarter, according to the company in its most recent 13F filing with the...
MarketBeat·1mo ago
<
1
2
...
>

Latest JANX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.